Found 305 matches for
What do a mathematician, an epidemiologist, a vaccine developer, a protein crystallographer and a whole bevy of immunologists and infectious disease specialists have in common? Answer: they’re just some of the Oxford University researchers coming together to fight the novel Coronavirus outbreak. Science blog by Charvy Narain
5 August 2022
The Medicine Quality Research Group organised a multidisciplinary hybrid meeting at Keble College, Oxford, July 3 to 6, for the FORESFA project ‘Forensic epidemiology and impact of substandard and falsified antimicrobials on public health’, funded by a Wellcome Collaborative Award.
20 July 2022
Patients affected by COVID-19 should be treated according to the severity of their disease. However, not all key national or international organisations define severity in the same way. This imprecision in severity assessment compromises the validity of some therapeutic recommendations. Using individual patient data would better guide and improve therapeutic recommendations for COVID-19.
12 July 2022
Researchers have launched a new study to improve our understanding of monkeypox disease. The first patients have now been recruited at Hôpitaux Universitaires de Genève (HUG) in Switzerland
6 July 2022
The University of Oxford’s Pandemic Sciences Institute (PSI) has been formally launched at a two-day event at the Blavatnik School of Government, at which the lead researchers set out its direction and strategy for the next five years.The PSI will draw together academics and experts from across the University to build a multi-disciplinary institute focused on reducing the risk from infectious threats through science, innovation and building global preparedness.
MORU OCGHR SMRU
28 June 2022
Microscopic examination of Giemsa-stained blood films is key to quantifying and detecting malaria parasites but there can be difficulties in ensuring both a high-quality manual reading and inter-reader reliability. The EasyScan GO was developed as a potential solution to this, a microscopy device using machine-learning-based image analysis for automated parasite detection and quantification.
Conferences & meetings OCGHR
24 June 2022
To tackle disease we need evidence to be generated through every type of health research study. This conference aims to bring together health research teams, organisations, health-workers, policy makers and practitioners to explore together how health research can be embedded into every healthcare setting. Join us at The Global Health Network Conference 2022 at the University of Cape Town, South Africa, 24 – 25 November 2022
The inside story of Recovery: how the world’s largest COVID-19 trial transformed treatment – and what it could do for other diseases
21 June 2022
Two years ago, the Recovery trial transformed the care of COVID patients with its dexamethasone announcement. Within four hours, the steroid was included in NHS treatment recommendations. Almost overnight, treatment of COVID patients around the world changed completely. It has been estimated that dexamethasone may have saved a million lives in the first nine months following the announcement. Recovery is a groundbreaking scientific machine which, from the outset, moved at unprecedented speed. In the first 100 days alone, the trial produced three groundbreaking results that would completely reshape COVID care.
Awards & Appointments OCGHR
21 June 2022
Dr Gail Carson from the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) is nominated chair of WHO Global Outbreak Alert & Response Network (GOARN)
16 June 2022
Two years ago, the RECOVERY trial gave the world its first breakthrough against coronavirus: the discovery that an inexpensive steroid pill, dexamethasone, reduced deaths by up to a third from COVID-1. Within hours, the result was breaking news across the world and hospitals were adopting the drug into the standard care given to all patients with COVID-19. In the nine months following the discovery, dexamethasone saved an estimated one million lives worldwide.
Congratulations to Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George!
Awards & Appointments MORU OCGHR
7 June 2022
David Warrell, MORU founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!
20 May 2022
The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.
27 April 2022
The Indian government’s Union Cabinet, chaired by Prime Minister Shri Narendra Modi, has approved a Memorandum of Understanding (MoU) between the Indian Council of Medical Research (ICMR) and the Infectious Diseases Data Observatory (IDDO), based at the University of Oxford.
1 April 2022
The Global Research on Antimicrobial Resistance (GRAM) Project has a new centre of operations at the University of Oxford, after moving this month from the Big Data Institute to the Centre for Tropical Medicine and Global Health, under the leadership of Dr. Benn Sartorius (PI) and Prof. Christiane Dolecek (co-PI).
29 March 2022
The Indian Council for Medical Research (ICMR) National Institute of Malaria Research (NIMR) and IDDO collaborate on a joint capacity building venture to train young researchers across three infectious diseases: malaria, visceral leishmaniasis and lymphatic filariasis
Artemisinin combination therapy trials need longer follow-up to detect late treatment failures for Plasmodium falciparum malaria
29 March 2022
WWARN researchers have been assessing the recommended minimum follow-up period in capturing polymerase chain reaction (PCR)-confirmed recrudescence following treatment with fixed-dose artemisinin combination therapies (ACTs) for patients with uncomplicated Plasmodium falciparum malaria.
Paxlovid to be investigated by the RECOVERY Trial as a potential treatment for patients hospitalised with COVID-19
29 March 2022
The RECOVERY Trial begins testing the antiviral treatment Paxlovid. Paxlovid, an oral antiviral treatment developed by Pfizer, is a combination of nirmatrelvir and ritonavir. Nirmatrelvir inhibits an enzyme that is critical for the replication of the virus that causes COVID-19, whilst ritonavir increases the concentration of nirmatrelvir.
28 March 2022
One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of countless researchers, doctors, nurses, statisticians and supporting staff.
18 March 2022
The world’s largest clinical trial investigating treatments for COVID-19 has now launched in Ghana, West Africa. This is the sixth country to take part in RECOVERY, joining Indonesia, Nepal, South Africa, Vietnam, and the United Kingdom.
11 March 2022
The University of Oxford in collaboration with the University of Maryland School of Medicine has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford. In the first study of its kind, after vaccination volunteers will be 'challenged' with paratyphoid to see whether the vaccine can prevent infection.
8 March 2022
A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group